Altimmune (ALT) Cash from Financing Activities (2010 - 2026)
Altimmune (ALT) reported Cash from Financing Activities of $78.5 million for Q1 2026, up 130.0% year-over-year from $34.1 million in Q1 2025, and down 3.27% on a QoQ basis from $81.1 million in Q4 2025.
Altimmune (ALT) has 17 years of Cash from Financing Activities data on file, last reported at $78.5 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 130.0% year-over-year to $78.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $251.2 million (up 465.45% YoY) and the FY2025 annual result came in at $206.8 million, up 1959.36% from the prior year.
- Cash from Financing Activities fell to $78.5 million in Q1 2026 per ALT's latest filing, from $81.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $81.1 million in Q4 2025 and bottomed at -$302000.0 in Q1 2023.
- The 5-year median for Cash from Financing Activities is $13.1 million (2023), against an average of $25.8 million.
- Peak annual rise in Cash from Financing Activities reached 169295.35% in 2023, while the deepest fall reached 109.49% in 2023.
- Tracing ALT's Cash from Financing Activities over 5 years: stood at -$43000.0 in 2022, then soared by 169295.35% to $72.8 million in 2023, then slumped by 86.14% to $10.1 million in 2024, then surged by 704.46% to $81.1 million in 2025, then decreased by 3.27% to $78.5 million in 2026.
- Per Business Quant, the three latest ALT Cash from Financing Activities figures stand at $78.5 million (Q1 2026), $81.1 million (Q4 2025), and $39.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 78.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.47 Mn |
| Mar 31, 2026 | 78.47 Mn |
| Dec 31, 2025 | 81.13 Mn |
| Dec 31, 2025 | 81.13 Mn |
| Sep 30, 2025 | 39.35 Mn |
| Sep 30, 2025 | 39.35 Mn |
| Jun 30, 2025 | 52.24 Mn |
| Jun 30, 2025 | 52.24 Mn |
| Mar 31, 2025 | 34.12 Mn |
| Mar 31, 2025 | 34.12 Mn |
| Dec 31, 2024 | 10.09 Mn |
| Dec 31, 2024 | 10.09 Mn |
| Sep 30, 2024 | 266,000.00 |
| Sep 30, 2024 | 266,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Mar 31, 2024 | -261,000.00 |
| Mar 31, 2024 | -261,000.00 |
| Dec 31, 2023 | 72.75 Mn |
| Dec 31, 2023 | 72.75 Mn |
| Sep 30, 2023 | 588,000.00 |
| Sep 30, 2023 | 588,000.00 |
| Jun 30, 2023 | 13.07 Mn |
| Jun 30, 2023 | 13.07 Mn |
| Mar 31, 2023 | -302,000.00 |
| Mar 31, 2023 | -302,000.00 |
| Dec 31, 2022 | -43,000.00 |
| Dec 31, 2022 | -43,000.00 |
| Sep 30, 2022 | 32.06 Mn |
| Sep 30, 2022 | 32.06 Mn |
| Jun 30, 2022 | 21.58 Mn |
| Jun 30, 2022 | 21.58 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 12.54 Mn |
| Dec 31, 2021 | 12.54 Mn |
| Sep 30, 2021 | 125,000.00 |
| Sep 30, 2021 | 125,000.00 |
| Jun 30, 2021 | 18.02 Mn |
| Jun 30, 2021 | 18.02 Mn |
| Mar 31, 2021 | 34.42 Mn |
| Mar 31, 2021 | 34.42 Mn |
| Dec 31, 2020 | 22.70 Mn |
| Dec 31, 2020 | 22.70 Mn |
| Sep 30, 2020 | 136.15 Mn |
| Sep 30, 2020 | 136.15 Mn |
| Jun 30, 2020 | 54.54 Mn |
| Jun 30, 2020 | 54.54 Mn |
| Mar 31, 2020 | 96,713.00 |
| Mar 31, 2020 | 96,713.00 |
| Dec 31, 2019 | 44,938.00 |
| Dec 31, 2019 | 44,938.00 |
| Sep 30, 2019 | -55,795.00 |
| Sep 30, 2019 | -55,795.00 |
| Jun 30, 2019 | -156,145.00 |
| Jun 30, 2019 | -156,145.00 |
| Mar 31, 2019 | 12.70 Mn |
| Mar 31, 2019 | 12.70 Mn |
| Dec 31, 2018 | 31.52 Mn |
| Dec 31, 2018 | 31.52 Mn |
| Sep 30, 2018 | 4.41 Mn |
| Sep 30, 2018 | 4.41 Mn |
| Jun 30, 2018 | -3.46 Mn |
| Jun 30, 2018 | -3.46 Mn |
| Mar 31, 2018 | 18,488.00 |
| Mar 31, 2018 | 18,488.00 |
| Sep 30, 2017 | 12.99 Mn |
| Sep 30, 2017 | 12.99 Mn |
| Jun 30, 2017 | -200,751.00 |
| Jun 30, 2017 | -200,751.00 |
| Mar 31, 2017 | 3.05 Mn |
| Mar 31, 2017 | 3.05 Mn |
| Dec 31, 2016 | -691,887.00 |
| Dec 31, 2016 | -691,887.00 |
| Sep 30, 2016 | 2.06 Mn |
| Sep 30, 2016 | 2.06 Mn |
| Jun 30, 2016 | 3.59 Mn |
| Jun 30, 2016 | 3.59 Mn |
| Mar 31, 2016 | 22,352.00 |
| Mar 31, 2016 | 22,352.00 |
| Dec 31, 2015 | 29,531.00 |
| Dec 31, 2015 | 29,531.00 |
| Sep 30, 2015 | 317,047.00 |
| Sep 30, 2015 | 317,047.00 |
| Jun 30, 2015 | 42,214.00 |
| Jun 30, 2015 | 42,214.00 |
| Mar 31, 2015 | -165,667.00 |
| Mar 31, 2015 | -165,667.00 |
| Dec 31, 2014 | 2.55 Mn |
| Dec 31, 2014 | 2.55 Mn |
| Sep 30, 2014 | 10.50 Mn |
| Sep 30, 2014 | 10.50 Mn |
| Jun 30, 2014 | 2.31 Mn |
| Jun 30, 2014 | 2.31 Mn |
| Mar 31, 2014 | 1.38 Mn |
| Mar 31, 2014 | 1.38 Mn |
| Dec 31, 2013 | 791,741.00 |
| Dec 31, 2013 | 791,741.00 |
| Sep 30, 2013 | 840,346.00 |
| Sep 30, 2013 | 840,346.00 |
| Jun 30, 2013 | 3.46 Mn |
| Jun 30, 2013 | 3.46 Mn |
| Mar 31, 2013 | -60,361.00 |
| Mar 31, 2013 | -60,361.00 |
| Dec 31, 2012 | 122,137.00 |
| Dec 31, 2012 | 122,137.00 |
| Sep 30, 2012 | 1.21 Mn |
| Sep 30, 2012 | 1.21 Mn |
| Jun 30, 2012 | -815,051.00 |
| Jun 30, 2012 | -815,051.00 |
| Mar 31, 2012 | 3.20 Mn |
| Mar 31, 2012 | 3.20 Mn |
| Dec 31, 2011 | 31,051.00 |
| Dec 31, 2011 | 31,051.00 |
| Sep 30, 2011 | -47,919.00 |
| Sep 30, 2011 | -47,919.00 |
| Jun 30, 2011 | 5.79 Mn |
| Jun 30, 2011 | 5.79 Mn |
| Mar 31, 2011 | 12,760.00 |
| Mar 31, 2011 | 12,760.00 |
| Dec 31, 2010 | 15.88 Mn |
| Dec 31, 2010 | 15.88 Mn |
| Sep 30, 2010 | 3.47 Mn |
| Sep 30, 2010 | 3.47 Mn |